PMID- 21551167
OWN - NLM
STAT- MEDLINE
DCOM- 20110822
LR  - 20220309
IS  - 1479-683X (Electronic)
IS  - 0804-4643 (Linking)
VI  - 165
IP  - 1
DP  - 2011 Jul
TI  - Gender-related differences in MEN1 lesion occurrence and diagnosis: a cohort 
      study of 734 cases from the Groupe d'etude des Tumeurs Endocrines.
PG  - 97-105
LID - 10.1530/EJE-10-0950 [doi]
AB  - CONTEXT: Multiple endocrine neoplasia type 1 (MEN1) disease is an autosomal 
      dominant syndrome that is believed to equally affect men and women. This 
      assumption has never been confirmed. OBJECTIVE: The aims of this study were to 
      evaluate the impact of gender on the prevalence of MEN1 lesions, on their 
      lifetime probability of occurrence, and on the diagnosis of MEN1. DESIGN: Data 
      regarding a study of 734 cases of MEN1 from the multicenter 'Groupe d'etude des 
      Tumeurs Endocrines' were analyzed. RESULTS: There were 57.8% females. The 
      prevalence and probability of pancreatic tumors were higher in males than in 
      females (P=0.06, P=0.0004). This difference was due to gastrinomas. The 
      prevalence and probability of developing pituitary tumors were significantly 
      greater in females (P<0.001, P<0.0001). Thymic tumors were exclusively found in 
      men. There were no significant gender differences in the prevalence and the 
      probability of developing hyperparathyroidism, or adrenal and bronchial tumors, 
      or in the proportion of positive genetic tests. A family history of MEN1 was more 
      frequently found in men than in women at the time of diagnosis (P=0.02). In the 
      case of pituitary tumor, the proportion of patients diagnosed with MEN1 at the 
      time of the first lesion was lower in women (44.2%) than in men (67.3%). 
      CONCLUSION: The phenotype expression of the MEN1 disease gene was different in 
      males and females. In female patients, the possibility of MEN1 is not 
      sufficiently taken into account. Any patient presenting a lesion that belongs to 
      the MEN1 spectrum, such as a pituitary tumor, should be closely questioned about 
      their family history and should be tested for hypercalcemia.
FAU - Goudet, P
AU  - Goudet P
AD  - Centre Hospitalier Universitaire de Dijon, Service de Chirurgie Endocrinienne, 
      Dijon, France. pierre.goudet@chu-dijon.fr
FAU - Bonithon-Kopp, C
AU  - Bonithon-Kopp C
FAU - Murat, A
AU  - Murat A
FAU - Ruszniewski, P
AU  - Ruszniewski P
FAU - Niccoli, P
AU  - Niccoli P
FAU - Menegaux, F
AU  - Menegaux F
FAU - Chabrier, G
AU  - Chabrier G
FAU - Borson-Chazot, F
AU  - Borson-Chazot F
FAU - Tabarin, A
AU  - Tabarin A
FAU - Bouchard, P
AU  - Bouchard P
FAU - Cadiot, G
AU  - Cadiot G
FAU - Beckers, A
AU  - Beckers A
FAU - Guilhem, I
AU  - Guilhem I
FAU - Chabre, O
AU  - Chabre O
FAU - Caron, P
AU  - Caron P
FAU - Du Boullay, H
AU  - Du Boullay H
FAU - Verges, B
AU  - Verges B
FAU - Cardot-Bauters, C
AU  - Cardot-Bauters C
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20110506
PL  - England
TA  - Eur J Endocrinol
JT  - European journal of endocrinology
JID - 9423848
SB  - IM
MH  - Adult
MH  - Cohort Studies
MH  - Female
MH  - France/epidemiology
MH  - Gastrinoma/diagnosis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multiple Endocrine Neoplasia Type 1/diagnosis/epidemiology/genetics/*pathology
MH  - Pancreatic Neoplasms/diagnosis/epidemiology
MH  - Pituitary Neoplasms/diagnosis
MH  - Prevalence
MH  - Sex Factors
MH  - Thymus Neoplasms/epidemiology
EDAT- 2011/05/10 06:00
MHDA- 2011/08/23 06:00
CRDT- 2011/05/10 06:00
PHST- 2011/05/10 06:00 [entrez]
PHST- 2011/05/10 06:00 [pubmed]
PHST- 2011/08/23 06:00 [medline]
AID - EJE-10-0950 [pii]
AID - 10.1530/EJE-10-0950 [doi]
PST - ppublish
SO  - Eur J Endocrinol. 2011 Jul;165(1):97-105. doi: 10.1530/EJE-10-0950. Epub 2011 May 
      6.